For The Better

Despite being up over 30,000% in the past 10 years, Celsius stock still has a lot of growth potential.

The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.

The stock trades at a higher-than-normal earnings multiple, and that could be a problem.

The hot stock nearly doubled this year. What’s next?

The investment firm put a $1,500 price target on the stock for 2026.

We also talk with Dexcom CEO Kevin Sayer about the impact of weight loss drugs on diabetes care.

Even as market participants wait for the latest from the Federal Reserve, some companies are having issues of their own.

CosMc’s could revitalize a high-profit part of the McDonald’s business model.

Luckin Coffee and Soho House look poised for sustainable growth in the new year and beyond.

The tech sector stalwart enjoyed a record-setting fiscal first quarter, but headwinds are brewing.

The key word for retail in 2022 was “inventory.” This year, it’s “shrink.”

AT&T illustrates the difference a big dividend can make over time. But there is more to this story.

It’s got its faults to be sure. For now and the foreseeable future, though, the tobacco giant has much to offer newcomers.

Snowflake is the latest AI company to offer customers immersive bootcamps to experiment with its products.

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.

Apple isn’t the only red-hot growth stock that’s held in the Berkshire Hathaway portfolio.

Tesla is seeing some headwinds creep into its investment thesis.

The bank stock is down 22% since 2022, but it may be an intriguing investment opportunity for one reason.

Shares in this cruise ship operator have soared in 2023. But is it a value trap for investors?